Viral host resistance studies.
A foremost objective of preclinical immunotoxicity testing is to address whether or not a drug or environmental toxicant causes adverse effects on net immune health, expressly the host's ability to mount an appropriate immune response to clear infectious organisms. Given the complex interactions, diverse molecular signaling events, and redundancies of immunity that has itself been subdivided into interdependent arms, namely innate, adaptive, and humoral, the results of single immune parameter testing may not reflect the final outcome of a drug or toxicant's effect on net immune health. The most comprehensive experimental approach to ascertain this information is utilization of host resistance models. Herein, application of viral host resistance models in rodents and non-human primates is described. Although brief descriptions of numerous viral models are discussed including reovirus, Epstein-Barr virus, cytomegalovirus, and lymphocryptovirus, the most well-characterized viral host resistance model, rodent influenza, is emphasized.
Freebern
Wendy Jo
WJ
D000818:Animals; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects / Q000276:immunology; D007251:Influenza, Human / Q000276:immunology; D007962:Leukocytes / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology; D023421:Models, Animal; D011323:Primates / Q000276:immunology; D014777:Virus Diseases / Q000276:immunology*; D017735:Virus Latency